Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is testing a new drug called XNW5004 in combination with enzalutamide for men with metastatic castration-resistant prostate cancer — meaning the cancer has spread and is no longer responding to hormone therapy that lowers testosterone. **You may be eligible if...** - You are 18 or older with a life expectancy of at least 3 months - You have prostate cancer confirmed by biopsy that has spread to other parts of the body - Your testosterone is at castration levels (very low) due to medication or surgery - Your cancer has progressed despite hormone therapy - You have previously been treated with abiraterone acetate and it stopped working **You may NOT be eligible if...** - You have a type of prostate cancer other than adenocarcinoma (such as small cell or neuroendocrine) - Your general health is poor (ECOG performance status above 1) - You have not had prior abiraterone treatment Talk to your doctor to see if this trial is right for you.